Clinical Potassium Pilot Study
Launched by MEDICAL UNIVERSITY OF GRAZ · Jan 30, 2020
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Cardiovascular diseases are among the leading causes of death in industrialized countries. Medical therapy for these diseases has seen significant progress, much of which is based on agents interfering with the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, mineralocorticoid receptor antagonists, neprilysin inhibitors). However, these agents bear the side effect of reducing renal potassium (K+) excretion and may thus lead to elevation of blood K+ Levels (hyperkalemia). Hyperkalemia is a potentially life-threatening condition...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 to 90 years of age
- • End stage-renal disease or acute kidney injury patient undergoing hemodialysis
- • Ability to provide oral and written informed consent
- • Ability and willingness to comply with study procedures
- • Willingness to not consume foods or drinks other than water during dialysis session
- Exclusion Criteria:
- • Intraventricular conduction abnormalities (left- or right bundle branch block, trifascicular block) which interfere with K+ECG determination
- • Active inflammation or infection of the oral mucous membranes or dentition
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, Styria, Austria
Patients applied
Trial Officials
Alexander H. Kirsch, MD
Principal Investigator
Medical University of Graz
Andras T. Deak, MD
Principal Investigator
Medical University of Graz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials